Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Intermittent Dosing Strategy Helps Thrombocytopenia Related to MDM2 Inhibitor Milademetan

      April 23, 2023
      By Chris Ryan
      Article

      Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.

      Intermittent Dosing Strategy Helps Thrombocytopenia Related to Milademetan in Sarcomas

      Intermittent Dosing Strategy Helps Thrombocytopenia Related to Milademetan in Sarcomas

      Through an intermittent dosing schedule, thrombocytopenia related to treatments with the MDM2 inhibitor milademetan (RAIN-32) in patients with sarcomas, and other solid tumors, may be mitigated, according to Chiara Fabbroni, MD.1

      In a presentation at the 2023 ESMO Sarcoma and Rare Cancers Congress, Fabbroni noted that dose interruptions and reductions could prevent unnecessary treatment withdrawal, making them the preferred management options for thrombocytopenia associated with milademetan.

      “Thrombocytopenia can be a problem in the use of milademetan. Sometimes it can be as deep as to require transfusion,” Fabbroni said. “However, when it does not require transfusion, the best management option here is to pause the treatment and resume it at a lower dose.” Fabbroni is a member of the Rare Cancer Unit at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy.

      Nausea is another common AE linked with treatment with milademetan, Fabbroni noted. The use of antiemetics, such as 5HT-3 antagonists and benzodiazepines, could help prevent and manage nausea and/or vomiting in patients receiving the MDM2 inhibitor.

      “Nausea can be referred as a symptom that can differ from one patient to another. Some patients refer to it as a symptom that starts at the beginning of [dosing], so from day one, and last all the days of [treatment],” Fabbroni said. “Some other patients refer [to] it as a symptom that also lasts for few days after [treatment]. It can be a symptom that really can affect quality of life of our patients.”

      MDM2 amplification occurs in approximately 3.5% to 7.0% of patients across a broad range of solid tumors; however, there is currently no defined copy number threshold for defining MDM2 status.2,3 Additionally, MDM2 amplification can occur in the absence of TP53 mutations in several malignancies, including sarcoma, urothelial carcinoma, cholangiocarcinoma, and lung cancer.

      Milademetan is a small-molecule MDM2-p53 inhibitor with a mechanism of action designed to reactivate p53 to induce apoptosis of TP53 wild-type malignant cells.1

      “The selective toxicity on platelets that is typical of the MDM2 inhibitor class of drugs is likely due to the role played by p53 in the regulatory mechanism of megakaryocytes,” Fabbroni explained. “Namely, it is able to induce [apoptosis of] megakaryocyte progenitors and to affect megakaryocytes, [thereby] impairing the number of platelets.”

      Safety data for milademetan have been documented in the phase 1 U101 trial (NCT01877382) in patients with advanced solid tumors. Additionally, the phase 3 MANTRA trial (NCT04979442) investigated milademetan in patients with dedifferentiated liposarcoma (DDLPS), and the ongoing phase 2 MANTRA-2 trial (NCT05012397) is further investigating the MDM2 inhibitor in patients with advanced/metastatic solid tumors with an MDM2 amplification.

      U101 included patients with advanced solid tumors or lymphomas, and investigators preferentially enrolled patients with tumor types associated with a high prevalence of MDM2 amplification or overexpression.4

      In the dose-escalation portion of the study, patients (n = 87) received milademetan on varying dose schedules. On the extended scheduled, the MDM2 inhibitor was given on days 1 to 21 of each 28-day cycle, and on the continuous schedule, milademetan was administered daily during each 28-day cycle. Two intermittent dosing schedules were also evaluated, including milademetan given once per day on days 1 to 7 of each 28-day cycle, as well as once per day on days 1 to 3 and days 15 to 17 of each 28-day cycle.

      In dose expansion, patients (n = 20) received milademetan at 120 mg on days 1 to 21 every 28 days.

      “This phase 1 study was to test different dose schedules. In one intermittent [schedule], milademetan [was] given at 260 mg from days 1 to 3 and days 15 to 17, every 4 weeks. That resulted as the best [dosing schedule] in terms of tolerability [and] maintaining efficacy,” Fabbroni said.

      Regarding safety, the rates of any-grade and grade 3 or higher thrombocytopenia were 45% and 15%, respectively, in patients treated with 260 mg of milademetan on days 1 to 3 and 15 to 17 (n = 20). In patients treated on all other schedules (n = 78), the rates of any-grade and grade 3 or higher thrombocytopenia were 67% and 35%, respectively. Notably, no episodes of bleeding related to thrombocytopenia were reported in any patients.

      Other hematological AEs in the intermittent dosing cohort included anemia (any-grade, 20%; grade ≥3, 0%) and neutropenia (any-grade, 10%; grade ≥3, 5%). In all other dosing cohorts, the rates of any-grade and grade 3 or higher AEs were 42% and 18%, respectively, for anemia, and 29% and 19%, respectively, for neutropenia.

      Any-grade nausea and vomiting occurred in 80% and 50% of patients in the intermittent dosing cohort, respectively. Those rates were 73% and 28%, respectively, in all other cohorts.

      MANTRA enrolled patients with unresectable and/or metastatic DDLPS, with or without a well-differentiated component. Patients were required to have progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy.

      Patients were randomly assigned 1:1 to receive 260 mg of milademetan on days 1 to 3 every 2 weeks or 1.5 mg/m2 of trabectedin as a 24-hour infusion once every 3 weeks. The primary end point of the study was progression-free survival (PFS) per blinded independent central review (BICR), and secondary end points included overall survival (OS), disease control rate (DCR), objective response rate (ORR), duration of response (DOR), investigator-assessed PFS, safety, and patient-reported outcomes.

      Results from MANTRA are expected to read out in the first half of 2023.

      In the ongoing MANTRA-2 study, patients are required to have locally advanced or metastatic TP53 wild-type solid tumors harboring an MDM2 amplification with a copy number of at least 8. Patients also need to have received all standard-of-care therapy appropriate for their tumor type and stage. All patients are receiving 260 mg of milademetan on days 1 to 3 every 2 weeks, with treatment continuing until disease progression, unmanageable toxicity, or other discontinuation criteria are met.

      ORR is serving as the trial’s primary end point, and secondary end points consist of DOR, PFS, growth modulation index, DCR, OS, and health-related quality of life.

      Among patients evaluable for safety from MANTRA-2 (n = 15) as of October 26, 2022, 27% experienced any-grade thrombocytopenia, including 20% who had grade 3 or higher thrombocytopenia.5 The rates of any-grade nausea and vomiting were 20% and 27%, respectively, and no grade 3 or higher events were reported for either AE.

      “The [safety] results of the phase 2 study [thus far] were consistent with the ones previously observed in the phase 1 [trial], with thrombocytopenia and nausea as the most frequent [AEs] reported,” Fabbroni said.

      When comparing the known safety profile of milademetan with other MDM2 inhibitors being evaluated in patients with sarcomas, such as siremadlin (HDM201), navtemadlin (KRT-232), and BI 907828, Fabbroni noted that the rates of thrombocytopenia and nausea were similar between milademetan and those agents.

      With thrombocytopenia and nausea commonly associated with treatment with MDM2 inhibitors, Fabbroni said properly managing these AEs is necessary to ensure patients are able to continue treatment and derive potential efficacy from milademetan.

      “The best thing to do is to personalize treatment as much as we can in order to maintain patients compliance and to optimize the potential benefit of [milademetan],” Fabbroni concluded.

      Disclosure: Dr Fabbroni reported institutional financial interest in Advenchen, Amgen Dompe, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Epizyme, GlaxoSmithKline, Karyopharm, Novartis, Pfizer, PharmaMar, Rain Oncology, and SpringWorks Therapeutics.

      References

      1. Fabbroni C, Jones RL, Linback T, MacNeilly E, Xu F, Simeral L. MDM2 inhibitor milademetan: safety profile and management of adverse effects. Ann Oncol. 2023;8(suppl 3):101026. doi:10.1016/esmoop/esmoop101026
      2. Kato S, Ross JS, Gay L, et al. Analysis of MDM2 amplification: next-generation sequencing of patients with diverse malignancies. JCO Precis Oncol. 2018;2018:PO.17.00235. doi:10.1200/PO.17.00235
      3. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453-3459. doi:10.1093/nar/26.15.3453
      4. Gounder MM, Bauer TM, Schwartz GK, et al. A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas. J Clin Oncol. 2023;41(9):1714-1724. doi:10.1200/JCO.22.01285
      5. Fabbroni C, Jones RL, Napolitano A, et al. MDM2 inhibitor milademetan: safety profile and management of adverse events. Presented at: 2023 British Sarcoma Group Conference; March 22-23, 2023; Newport, Wales.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a woman with shoulder-length black hair wearing headphones and a white sweater
      Image of a woman with a blue background
      Image of a man in scrubs with short hair and glasses
      Photo of Jamie Carroll, APRN, CNP, MSN, from a video call with an Oncology Nursing News branded border around the frame
      Medium closeup shot of a women in front of a dark blue background with graphics that read "All in Against Cancer" and "Ochsner Health"
      woman in front of a dark blue background for Oschner Health
      woman in front of a blue background with dark hair
      Related Content

      Photo of three nurses walking together in a hospital

      Oncology Nurses Report Heavier Workloads in the Wake of COVID-19

      Roman Fabbricatore
      April 13th 2025
      Article

      Providing education about patients’ diseases was difficult, according to 32% of registered nurses and 29% of infusion nurses.


      The Vitals

      ASH Data Offer Treatment Direction for Oncology Nursing Professionals

      Lindsay Fischer
      February 1st 2023
      Podcast

      Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss practice-changing presentations from the 64th American Society of Hematology Annual Meeting and Exposition.


      Photo of a woman in scrubs sitting in front of a laptop at a desk with her hand on her neck and an exhausted expression

      Non-Redeployment and Telemedicine Linked to COVID-19 Burnout For Oncology PAs

      Bridget Hoyt
      April 1st 2025
      Article

      Rates of pay, bonus pay, and changes to funding for continuing education were not significantly linked with burnout rates.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Illustration of the gastrointestinal tract surrounded by three characters holding various medications and a magnifying glass

      Optimizing First-Line Therapy for BRAF-Mutant Colorectal Cancer

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      March 5th 2025
      Article

      Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment.


      Line illustration of two bones and connective tissue

      OH2 Shows Safety and Anticancer Response with HX008 for Advanced Sarcoma

      Kyle Doherty
      March 3rd 2025
      Article

      Preliminary findings suggest that OH2 monotherapy is safe, with promising responses observed when combined with HX008 in locally advanced or metastatic sarcoma.

      Related Content

      Photo of three nurses walking together in a hospital

      Oncology Nurses Report Heavier Workloads in the Wake of COVID-19

      Roman Fabbricatore
      April 13th 2025
      Article

      Providing education about patients’ diseases was difficult, according to 32% of registered nurses and 29% of infusion nurses.


      The Vitals

      ASH Data Offer Treatment Direction for Oncology Nursing Professionals

      Lindsay Fischer
      February 1st 2023
      Podcast

      Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss practice-changing presentations from the 64th American Society of Hematology Annual Meeting and Exposition.


      Photo of a woman in scrubs sitting in front of a laptop at a desk with her hand on her neck and an exhausted expression

      Non-Redeployment and Telemedicine Linked to COVID-19 Burnout For Oncology PAs

      Bridget Hoyt
      April 1st 2025
      Article

      Rates of pay, bonus pay, and changes to funding for continuing education were not significantly linked with burnout rates.


      The Vitals

      Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

      Lindsay Fischer
      January 16th 2023
      Podcast

      Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.


      Illustration of the gastrointestinal tract surrounded by three characters holding various medications and a magnifying glass

      Optimizing First-Line Therapy for BRAF-Mutant Colorectal Cancer

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      March 5th 2025
      Article

      Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment.


      Line illustration of two bones and connective tissue

      OH2 Shows Safety and Anticancer Response with HX008 for Advanced Sarcoma

      Kyle Doherty
      March 3rd 2025
      Article

      Preliminary findings suggest that OH2 monotherapy is safe, with promising responses observed when combined with HX008 in locally advanced or metastatic sarcoma.

      Latest Conference Coverage

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.